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CHAPTER I 
INTRODUCTION 
Macrophages play a vital role in the mammalian 
host immune response against a multiplicity of invasive 
agents including neoplasms (80), bacteria (87), ·protozoa 
(86), and fungi (79). The macrophage is capable of an 
extensive range of responses to these agents. The type 
of response is dependent upon the size and type of 
target. Targets such as tumor cells or large micro-
organisms are attacked in an extracellular manner while 
most bacteria, yeast, and small protozoans are phago-
cytosed and destroyed within the macrophage (2). 
comparisons of extracellular tumoricidal activity and 
intracellular bactericidal activity of macrophages have 
been found to be highly dependent upon method of 
activation, target type, target state and duration of 
the experiment (41). Different populations of activated 
macrophages which have been defined by one functional 
criterion do not always possess other functional 
characteristics of activated macrophages (130). This 
has been shown in studies where different levels of 
macrophage cytocidal activity were observed for extra-
cellular tumor cell killing versus intracellular fungal 
1 
(114) or parasite killing (88,95). 
The purpose of this investigation has been to 
compare the extracellular fungicidal and tumoricidal 
activities of four macrophage groups. The groups were 
defined as described previously (82). These groups of 
macrophages were assessed for tumoricidal activity via 
release of 5lcr from EL-4 tumor cells and for fungicidal 
activity by inhibition of yeast formation following 
induction of Candida albicans hyphae. Both of these 
assays measure the ability of macrophages to kill target 
cells in an extracellular manner (16,46). Such a 
comparison of extracellular cytocidal activity for both 
Candida and tumor cells, by identical groups of macro-
phages, has not been reported previously. In this study 
a correlation has been demonstrated between the acqui-
sition and loss of extracellular tumoricidal and 
fungicidal activity by these four groups of macrophages. 
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CHAPTER II 
LITERATURE REVIEW 
~. albicans, is an opportunistic, dimorphic 
fungus commonly found as part of the normal flora of 
many mammals, including man. Diabetes, neoplasms, 
immunological defects, and immunosuppressive therapy are 
factors which favor the pathogenic invasion of Candida 
and the development of systemic infection. The cellular 
immune system is believed to be of vital importance in 
the host response to a Candida infection. As an 
example, it is well known that disseminated candidiasis 
occurs at a high frequency in patients with chronic 
granulomatous disease or myeloperoxidase deficiency. 
The antimicrobial capacities of phagocytic cells are 
impaired in these patients resulting in increased 
infections (69). Therefore, cells of the phagocytic 
lineage are regarded as being critical in the host 
defense against systemic candidiasis. The phagocytic 
response occurs despite the fact that invasive lesions 
caused by ~. albicans characteristically contain hyphal 
forms which are typically too large to be ingested. Due 
to the large size of these hyphal fragments, phagocytic 
cells need to kill through an extracellular mechanism 
( 26) • 
3 
Cells of the phagocytic lineage are critical for 
host defense against fungi as well as neoplastic cells. 
Multiple fungicidal and tumoricidal mechanisms operate 
in normal monocytes (2,69). Damage to hyphae has been 
largely attributed to products of oxidative metabolism, 
although nonoxidative bactericidal activity of monocytes 
against Candida has been reported and may be important 
in some situations (25). Additionally, macrophages 
serve many roles in the immune response including; 
antigen processing, immune regulatory substance section, 
and the modulation of immune responsiveness (102). As a 
function of immune responsiveness, macrophages also have 
the ability to bind, react with, and kill neoplastic 
cells. This cytocidal event also occurs in an extra-
cellular manner and is potentially mediated by various 
macrophage factors. Tumoricidal effects may be mediated 
by either oxidative or non-oxidative mechanisms. 
Whether the macrophage killing mechanism for Candida and 
neoplastic cells is identical remains unknown and will 
be discussed below. 
Macrophages are known to possess varying cap-
abilities to respond to stimuli. These variances in 
response to the stimuli are referred to generally as 
"activation states" or "levels of activation." An 
evaluation of the comparative extracellular killing 
ability of macrophages at various levels of activation 
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is the purpose of this study. 
A. Macrophage activation 
1. Levels of activation. 
Macrophages play a major role in a wide variety 
of cellular defense mechanisms. Performance of these 
functions requires the simultaneous presence of effec-
tive activation signals and competent mononuclear 
phagocytes (83). These functional abilities are not a 
constitutive property of all mononuclear cells, rather 
such cells acquire these functions in response to 
various signals present in the immediate environment 
(44). Furthermore, macrophage-mediated resistance is 
localized, short-lived, and only regenerated by rein-
fection of the host (96). 
The monocyte/macrophage maturation sequence can 
be divided into four different phases in accordance with 
the work of Meltzer: I. Precursor, II. Primed, III. 
Triggered, and IV. Postcytolytic (82). In vivo this 
maturation or differentiation sequence occurs in the 
following manner: Phase I: Macrophages which are 
recruited and differentiated from immature blood-derived 
mononuclear phagocytes into competent lymphokine-
responsi ve cells by factors generated at the site of 
inflammation. Phase II: Inflammatory macrophages which 
have entered a priming stage in response to immuno-
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modulating factors, during which they are not yet 
cytotoxic for infectious agents or tumor cells. Phase 
III: Macrophages which have developed full functional 
activity via a triggering signal and are cytotoxic for 
infectious agents or tumor cells. Phase IV: Macrophages 
which had been functionally active, but have now 
returned to a functionally quiescent level. These 
phases of macrophage activation have been also described 
as I. Resident, II. Elicited, III. Activated, and IV. 
Postcytolytic (82). Such phases have been characterized 
extensively in vitro, and will be discussed further 
using this terminology. 
I. Resident 
Resident macrophages are cells present at any 
given site in the absence of an exogenous or inflam-
matory stimulus (85). Resident macrophages do not 
constitute a stable cellular population, but rather are 
constantly renewed by an influx of blood-derived 
monocytes and the continuous division of immature 
monocytes (125). Complete turnover of the macrophage 
population varies between one and two weeks. Migration 
of circulating monocytes into a tissue site provides for 
the majority of new cells, since dividing cells account 
for only 35% of the total cellular population (22). 
II. Elicited 
The term, "elicited", indicates an accumulation 
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of exudate macrophages at a particular site. Elicited 
macrophages are attracted to a given site by certain 
stimuli. Investigations of in vitro macrophage acti-
vation have normally been carried out with macrophages 
obtained 3-4 days after induction of inflammation in the 
peritoneal cavity (65). These cells are a heterogenous 
population composed of resident macrophages and those 
macrophages derived from emigrating blood monocytes 
responding to the inflammatory stimulus (22). Such 
induction also results in the accumulation of other cell 
types, such as lymphocytes, which have the potential for 
modulating the functional activity of macrophages. 
III. Activated 
The term "activated" macrophage was originally 
coined by Mackaness to define the enhanced non-specific 
resistance to intracellular bacteria observed in animals 
recovering from infection with Listeria monocytogenes 
(125). Activated macrophages are cells with increased 
functional activity induced by a given stimulus which 
either increases one or more of the functional activi-
ties of the cell or induces a new functional cellular 
activity. The process of macrophage activation is not 
the result of a single interaction between the signal 
and cell, but appears to be the final step of an 
activation process which requires a defined progressive 
sequence of reactions for complete cellular activation 
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(82,83,105). 
IV. Postcytolytic 
Macrophages which have been activated for a 
prolonged period of time lose their cytocidal capabili-
ties. These macrophages have been maximally stimulated 
previously and have returned to a normal or resident 
level of cytocidal activity. These cells are in a 
terminal maturation stage, yet still maintain respons-
iveness to proper stimuli, and can return to a cytocidal 
state (82). 
The pathway of macrophage differentiation leading 
to the acquisition of nonspecific tumoricidal capability 
proceeds along a continuum from the unaltered resident, 
to the activated macrophage, returning to a noncytolytic 
cell (128). Accordingly, macrophages have adapted the 
ability to become directly responsive to microbes, and 
to molecules arising from microbial degradation (75). 
In addition, macrophages are responsive to lymphokines 
produced by other cellular defense mechanisms (35). The 
ability to respond in this manner is an evolutionary 
advantage which allows the macrophage to react in a 
varied context to different stimuli (68). 
The induction of macrophage cytotoxic reactions 
by any of several different primary activation signals 
is regulated (either amplified or suppressed) in turn by 
a variety of unrelated secondary signals (81). There-
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fore, not only can macrophages enhance their overall 
functional potential but also they can provide a 
selection of different functions. Each of these is 
capable of individual enhancement. This individual 
enhancement usually leads to concomitant suppression of 
other functions (2). 
Differences in macrophage response to activation 
signals are not necessarily related to the number of 
activation signal receptors present on a given cell 
(81). A resident macrophage may be more, less or 
equally responsive than an elicited cell to an activa-
tion signal. The responsiveness of the cell depends 
directly on the stimulus and state of the elicited cell 
(81). The ability of macrophages cultured in vitro to 
respond to activation signals and kill neoplastic or 
microbial targets changes with time in in vitro cell 
culture (81). Macrophages cultured in medium prior to 
addition of lymphokines, gradually lose the capacity to 
be activated (83). It is believed that the immature 
monocyte is responsive to stimuli for only a short 
period of time. The lack of responsiveness may account 
for the progressive decrease in cytotoxic activity of 
macrophages cultured for days in vitro (83). 
The cytocidal state of macrophages is mediated by 
specific signals such as lymphokines and lipopoly-
saccharide (LPS) but not by nonspecific inflammatory 
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stimuli such as thioglycollate (93). An increase in 
certain functions associated with the elicited macro-
phage, such as phenotypic markers or secretory proteins, 
are not accompanied always by an enhancement in bacter-
icidal activity (117). Elicited macrophages have been 
shown to possess different bactericidal activities 
(109). Likewise, the types of macrophages which are 
elicited may also vary. The thioglycollate-elictied 
macrophage response is dependent upon the age of the 
mouse from which the cells were derived. Thioglycollate 
can recruit macrophages drawn from a pool of older 
preformed monocytes or macrophages (54). These thio-
glycollate-elicited macrophages phagocytose more 
bacteria and therefore provide a more efficient cell for 
potential intracellular microbial growth (85). These 
cells have been shown to have lowered listericidal 
activity (117), suggesting that thioglycollate may 
impair antimicrobial activity (54). Furthermore, the 
responsiveness of elicitec macrophages may be modulated 
by endogenous microorganisms and/or microbial products 
(75). Therefore, the environment of the host may 
contribute to observed fluctuations in certain experi-
mental systems following thioglycollate elicitation 
(68). 
Some controversy exists as to the ability of 
thioglycollate macrophages to kill both tumor cells and 
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microbial targets (61). Furthermore, the ability of 
thioglycollate-elicited macrophages to be further 
activated to cytocidal states has been debated (96). 
Nathan (93) has found that peritoneal macrophages can be 
activated by LPS equally well whether they are resident 
or elicited. Other studies have found thioglycollate-
elicited macrophages to kill very well and to be further 
activated to cytocidal activity by LPS (31). Still 
other investigators have found thioglycollate-elicited 
macrophages to lack cytocidal ability for a variety of 
targets (11,61). These discrepancies may be attributed 
to the agar contained within macrophages elicited with 
thioglycollate (32) and the interference by agar in 
macrophage metabolism (31). Despite comparable glycogen 
content, resident macrophages take up glucose while 
thioglycollate-elicited macrophages do not, suggesting 
metabolic alteration resulting from agar uptake (31). 
Finally, macrophage properties relegated to nonspecific 
inflammatory influences may be rapidly bypassed by 
lymphokines which induce a microbicidal macrophage fully 
capable of functional activity. 
Macrophage precursors are induced by colony 
stimulating factors (CSF) to proliferate and dif-
ferentiate into macrophages. Under defined in vitro 
conditions, a resident macrophage arises from the 
progenitor cell (39). Macrophages derived from bone 
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marrow and treated with lymphokines or LPS induce 
similar maturation changes to that of resident macro-
phages being activated (53). However, activated bone 
marrow macrophages mediated ten times the tumoricidal 
activity of resident macrophages, while maintaining the 
cytocidal effect for a longer period of time (7). CSF 
has been shown to induce distinct morphological and 
metabolic alterations in resident macrophages. These 
modifications are clearly distinct from those induced 
with gamma interferon and appear to affect all cells of 
the culture (7). CSF also affects mature macrophage 
functions and metabolism resulting in an increase in 
RNA, DNA, and cell size along with synthesis and 
secretion of a variety of substances such as PGE2, 
interleukin-1, and proteases (7). 
2. Regulation of activation 
Despite the nonspecific manner in which activated 
macrophages express their cytotoxic effects, the 
sequence of events leading to the activated state 
require precise interaction of macrophages and appro-
priate stimuli (66). Resident macrophages can be 
induced to the priming stage by lymphokines. But, 
another trigger, such as LPS, is required before 
macrophages become fully activated (105). Several 
groups have found full cytotoxic activity is best 
obtained when LPS and a lymphokine, such as gamma 
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interferon (100), are synergistically combined (99,128). 
Priming or triggering of macrophages by LPS occurs at 
concentrations as low as 0.1 ng/ml, and increases in a 
dose-dependent manner (103). The period of macrophage 
activation and/or responsiveness is short-lived -
(83,105). In vitro macrophage activation to a tumor-
icidal state, in vitro by LPS has been shown to appear 
as early as 4 hours following stimulation. Maximal 
responsiveness is apparent for 6-16 hours and is lost 
by 36 hours (75,105). similar observations have been 
made in vivo where macrophages have been shown to lose 
their cytotoxic capacity quickly following an antigenic 
challenge (83). This decrease in cytotoxic activity is 
irreversible, but is not a consequence of changes in 
cell viability. Rather, it is the result of terminal 
maturation and differentiation of the cell population 
(82). 
It has been proposed by Pace and Russell that the 
role of the lymphokine is not to effect full activation 
but rather to increase macrophage sensitivity to the 
effects of LPS (99). Lymphokines acting alone, without 
LPS, fail to activate macrophages to cytocidal activity 
(99). Conversely, LPS has been shown by Weinberg to act 
as a signal for activation of macrophages in the absence 
of lymphocytes or their products (128). Furthermore, 
high doses (µg/ml) of LPS can activate an elicited 
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population of macrophages completely to both inhibit 
cell proliferation and provide a cytotoxic response 
without a requirement for lymphokines (75). 
The mechanism by which LPS modifies macrophage 
responsiveness is unclear, but it is likely that it 
initially acts at the level of the macrophage plasma 
membrane (128). LPS has been shown to associate both 
with artificial (12) and biological (64) membranes. 
Evidence exists that LPS interacts with cell membranes 
by associating with the plasma membrane, intercalating 
in the phospholipid bilayer, after which it is endo-
cytosed by the cell (60). These data suggest that 
modification of the macrophage membrane alter cytocidal 
capacities (124). Therefore, the insertion of LPS into 
the membrane and the perturbation of the membrane 
results in macrophage activation by transmitting the 
necessary signals from the membrane to the vacuolar 
system {60,124). The molecular basis of this phenomena 
is unknown. However, addition of LPS alters the 
cellular protein composition of the macrophage which 
then allows it to become functionally competent (44). 
There are several other major modifications of 
the macrophage membrane during the process of activa-
tion. Lipid composition correlates specifically with 
development of tumoricidal activity. Total lipid 
content of tumoricidal macrophages is far greater than 
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that of noncytolytic macrophages (109). Loss of 
tumoricidal activity directly parallels the loss of 
esterified cholesterol, suggesting that the macrophage 
activation process may be modulated by cellular lipid 
content (109). A high-molecular-weight serum lipo-
protein is responsible for modulation of macrophage 
cholesterol content (109). Macrophage activation to the 
tumoricidal state has also been shown to be calcium 
dependent (131). Calcium ionophore A23187 enhances 
secretion of a cytolytic factor from macrophages, while 
calcium channel blockers inhibit activation (131). This 
suggests calcium channel activity is linked with the 
biochemical reactions for devolvement and expression of 
macrophage functional activity. The release of the 
ionophore changes phosphoinositol lipid metabolism which 
results in the mobilization of calcium ions following 
activation (131). 
According to Drysdale et al. there exists two 
pathways by which macrophages may be activated (28). 
The first, is unaffected by the prostaglandin (PG) 
synthesis inhibitor, indomethacin. The second, is 
inhibited by indomethacin and is a consequence of 
activation by LPS or lymphokines (28). Low levels of 
PGEl or PGE2 will restore cytocidal activity in non-
activated cells cultured in vitro (84). But, PGE2 
inhibits macrophage activation as a negative feedback 
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signal, preventing nonspecific spreading of a cytocidal 
effect (110). Conditions which favor high PGE meta-
bolism result in the activation of resident and elicited 
macrophages while inhibiting activated macrophages 
(111). PGE2 accumulation in macrophage culture media 
has been claimed to be responsible for the concomittent 
loss of macrophage-mediated tumoricidal activity. 
Resident and elicited macrophages however, become 
tumoricidal when pretreated with PGE (111). The 
mechanism does not prevent the development of macrophage 
mediated cytolytic activity, but rather shuts it off 
once it develops full cytotoxic potential. Cultures 
treated with indomethacin sustain high levels of killing 
for long periods of time (120). Therefore, prostagland-
ins have differential effects on macrophage antitumor 
activity depending upon the prior activation state of 
the macrophage (120). 
Additionally, other suppressive accessory factors 
can be derived from endogenous and exogenous sources 
(81). Several studies have shown that tumor cell 
culture supernatants, tumor extracts, and sera from 
tumor-bearing animals possess suppressive properties for 
macrophages (60). Some neoplasms themselves contain 
increased amounts of PGs. As one example, factors 
released from the EL-4 cell line can suppress macrophage 
cytocidal activity against all microbial targets tested, 
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yet only selectively inhibit tumoricidal activity (81). 
Furthermore, suppression of the macrophage is limited to 
the site of the tumor (120), and products of activated 
macrophages that are normally associated with cytocidal 
activity have been implicated as possible mediators of 
the suppression (84). 
3. Biochemical and functional capacities of macrophages 
The process of macrophage activation results in 
extensive but selective alterations in macrophage 
properties (39). Resident, elicited, and activated 
mouse macrophages display marked phenotypic hetero-
geneity along with selective surface, secretory and 
endocytotic differences (39). This heterogeneity is 
observed consistently among these populations regardless 
of the site from which the macrophages were isolated 
( 3 9) • 
Microscopically, the most salient feature of the 
activated macrophage is the larger size which is 
expressed as a result of increased protein content (22). 
Macrophages secrete in excess of 50 different proteins 
(54). The secretion of these proteins depends both on 
the physiological state and activation level of the 
macrophage (54). The age and origin of the macrophage 
is very important as well, since secretion profiles are 
modified upon maturation and differentiation (54). Many 
proteins are constitutively produced by macrophages at 
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all activation levels (54), and products unique to 
activated macrophages represent less than 8% of their 
total secretory activity. 
Several groups of investigators have attempted to 
correlate various macrophage maturation markers (appear-
ance of receptors, either biochemical or physiological) 
to distinct stages of activation. This work has proven 
difficult to interpret due to the variable nature of 
activation mechanisms utilized. However, several 
characteristics of macrophages at different levels of 
activation appear to be consistently observed. (See 
Table 1). 
Macrophages which have been induced to the primed 
stage, share some, but not all of the properties common 
to activated cells (2). Activated and induced macro-
phages show an enhanced oxidative response to stimuli, 
relative to resident macrophages (63). Resident macro-
phages which functionally present some similarities to 
neutrophils, posses an efficient intracellular micro-
bicidal activity but are less actively fungicidal than 
neutrophils (25). Additionally, resident macrophages 
generally lack the ability to kill extracellular 
pathogenic fungi (14). 
B. cytocidal capacities of macrophages 
1. Candidacidal capacities 
18 
19 
Table 1. summary of Macrophage Characteristics 
Macrophage 
characteristic 
Intracellular enzymes 
Lysosomal hydrolases 
Alkaline phosphodi-
esterase 
B-galactosidase 
Surf ace receptors 
Fe 
Complement 
Man-GlcNac 
Ia 
5 1 -Nucleotidase 
CSF-1 
Secretory capacities 
Lysozyme 
Neutral proteases 
ROI release 
02-
H202 
Arachidonic acid 
metabolites 
Complement 
Monokines 
IL-1 
TNF 
cytotoxins 
Cellular characteristics 
Cell protein 
Spreading 
o2 uptake 
Glucose uptake 
Phagocytosis 
Cytocidal capacities 
Bind tumor 
Kill tumor 
Kill intracellular 
organisms 
Kill extracellular 
organisms 
I 
+ 
+++ 
+ 
+++ 
+++ 
+/-
+++ 
+++ 
++ 
+ 
+++ 
+ 
+ 
+ 
+ 
+ 
Level of activation 
II 
++ 
+ 
+++ 
++ 
+ 
+ 
+ 
+/-
+++ 
++ 
+ 
+ 
+ 
++ 
+ 
+ 
+ 
+ 
++ 
++ 
++ 
++ 
+ 
++ 
+ 
++ 
+ 
III 
+++ 
+++ 
+ 
+++ 
+ 
+ 
+++ 
+ 
++ 
+++ 
+++ 
+++ 
++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
(ref) 
2 
30 
75 
95 
34 
112 
112 
30 
39 
15 
4 
62 
115 
111 
34 
52 
38 
61 
54 
29 
112 
75 
29 
61 
61 
92 
122 
I, II, III, = Levels of activation. Incomplete data on 
level IV. -, +, ++, +++, = Relative levels of activity. 
+/- = Disputed, absent versus low levels. 
Invasive Candida albicans infections normally 
result in hyphal forms which are too large to be 
phagocytized (25). Early work by Diamond demonstrated 
that PMNs could damage and kill ~. albicans through non-
phagocytic means by adhering directly to the hyphae 
(56). Similarly, studies of macrophage-Candida inter-
actions have resulted in the same finding (26). 
Macrophages have a large and diverse arsenal with which 
to combat infectious agents. This is generally divided 
into two classifications 1) oxygen-dependent and 2) 
oxygen-independent. Reactive oxygen metabolites are 
responsible for much of the microbicidal (63) activity 
of macrophages, although killing by oxygen-independent 
mechanisms also occurs (72). 
Oxygen-dependent systems are classified as such 
due to a decrease in microbicidal activity under 
anaerobic conditions (115). The generation and secre-
tion of reactive oxygen intermediates (ROI) is the end 
result of a coordinated sequence of metabolic events 
termed the respiratory burst. This function is not 
constitutive, but must be acquired. Acquisition of 
competence to execute the respiratory burst involves 
modulation of the cellular and biochemical elements 
necessary for the production of ROI (62). Agents which 
activate macrophages alter the expression of cell 
surface receptors. The altered receptors then trigger 
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the respiratory burst (62). The respiratory burst can 
be modulated at a number of different mechanistic 
levels. These include; the amount and/or function of 
cell surface receptors, the amount and/or function of 
enzyme systems which generate the output, and the 
various elements which couple these two systems (2). 
All either directly or indirectly stimulate protein 
kinase c (PKC), suggesting PKC is a central element in 
stimulus-response coupling for the respiratory burst and 
secretion of ROI (62). 
The value of ROI in defense against Candida 
infection has been elucidated in studies of cells from 
patients with chronic granulomas disease and hereditary 
myeloperoxidase deficiencies (69). These along with 
studies utilizing ROI scavengers have shown that ROI 
(superoxide, hydrogen peroxide, singlet oxygen, and 
hydroxyl-free radicals) produced by the respiratory 
burst, all act in concert to mediate hyphal destruction 
(25). For example, superoxide (o2-) itself does not 
directly damage hyphae, but serves primarily as an 
intermediate in H2o2 production important to the 
myeloperoxidase-halide system (26). However, iodination 
has been shown to not be essential for myeloperoxidase-
media ted killing but is a non-casual sidelight of the 
candidacidal activity of macrophages (69). The candid-
acidal effects of singlet oxygen can be diminished by 
21 
quenching agents, such as histidine, suggesting a 
possible role for the molecule in hyphal destruction 
(26). Additionally, activated macrophages have been 
shown to produce high amounts of o2- in vivo and 
therefore may protect the host against Candida infec-
tions (23). Hyphal damage appears to result from 
products of oxidative metabolism, especially the 
myeloperoxidase-H2o2-halide system, but myeloperoxidase-
independent mechanisms are active as well (26). 
Furthermore, anaerobiosis significantly reduced, but did 
not eliminate, damage to hyphae by macrophages indicat-
ing at least some oxygen-independent mechanisms may be 
involved in target cell destruction (26). 
Macrophages possess a variety of hydrolytic 
enzymes which function in an oxygen-independent manner 
(23). These fungicidal constituents, such as B-glucos-
aminidase, are found within macrophage cytoplasmic 
granules such as lysosomes (69). Lysosomal constituents 
have been shown to be released by macrophages following 
contact with target cells and to be microbicidal (2,24). 
Two microbicidal cationic peptides (MCP-1 and MCP-2) 
produced by rabbit alveolar macrophages have been found 
by Patterson-Delafield §.t al. These peptides are 
effective against diverse gram positive and negative 
bacteria and fungi, and act either extracellularly or 
within the phagolysozome (73). These proteins, rich in 
22 
arginine and cystine, are distinct from histones and 
have been found to suppress cellular oxygen consumption 
by Candida (72). In studies using partially purified 
fractions of macrophages enriched for lysosomal granules 
Candida hyphae where not damaged (26). These results 
suggest that cationic proteins and perhaps other granule 
constituents might act as ancillary antifungal mechan-
isms, enhancing effects of oxidative mechanisms (97). 
Despite findings that suggest a role for oxygen-depen-
dent and oxygen-independent mechanisms for Candida 
killing, it remains unclear which intermediates or 
pathways are directly responsible for hyphal damage 
(25). Conflicting data regarding the ability of in vitro 
cultured macrophages to destroy ~. albicans has been 
reported. The disparity in results is a consequence of 
the utilization of mononuclear cells derived from: 
various sites, such as the blood (69), the peritoneum 
(23) or the alveoli (71); from various animal species, 
including mouse (62), man (69), and rabbit (71); as well 
as elicitation of the cellular populations with various 
in vivo adjuvants (51). Analysis is further complicated 
by the use of monocytes (69) or resident (63), induced 
(51), lipopolysaccharide (LPS)-activated (71), or 
lymphokine-activated (14) macrophages. Furthermore, 
many studies have used the capacity for intracellular 
killing of ingested yeasts to determine candidacidal 
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activity. This may not reflect the ability of the 
macrophage to damage hyphae at the cell surface by 
nonphagocytic mechanisms (26). such a non-standardized 
approach has made comparisons of macrophage activity 
difficult. 
It is known that contact between the macrophage 
and hyphae cell is vital for destruction of fungi in 
macrophages (37). Electron micrographs of monocyte-
Candida interactions have shown monocyte plasma mem-
branes adhering directly to portions of hyphal cell 
walls. Sections of hyphae in contact with the macro-
phage were partially engulfed, damaged and disrupted 
(26). This hyphal damage was accompanied by damage to 
the monocyte itself, in that many hyphae had surface-
adherent vesicles that were bounded by three-layer unit 
membranes (26). These studies did utilize peripheral 
blood monocytes and the lability of human monocytes 
compared with mature macrophages has been shown to be 
significant (19). 
During infections, yeast forms of Candida are 
found in tissue, although the prevalent form is the 
hyphal stage (11) • It has been suggested that hyphal 
forms of Candida are endowed with in vivo resistance to 
host phagocytic defenses via a variety of mechanisms 
(107). Adherence of macrophages to the hyphae has been 
shown to occur through a cell wall constituent, most 
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probably mannose, which then stimulates the respiratory 
burst (24). The release of this soluble material has 
been shown to then inhibit further macrophage activation 
resulting in suppression of macrophage function (90). 
Degradation by phagocytic cells, results in the reduc-
tion of target cell cytoplasm. Cell wall deformation 
and collapse are all a result of enzymatic breakdown of 
Candida cell wall mannan by macrophages (37). The most 
invasive adaptation of Candida is the ability to 
alternate between the yeast and hyphal forms during its 
multiplication. This has been related to its ability to 
evade host defenses (101). The transition between the 
two stages appears to be important in the expression of 
fungal pathogenicity, although no definitive evidence 
exists which compares relative pathogenicity with 
different morphologies. Possibly cell wall composition 
and architecture of the two forms under different 
conditions may force Candida toward morphological 
transition (70). 
2. Tumoricidal capacities 
Vital roles have been proposed for cellular 
immunity in the complex host reaction to neoplastic 
disease (47,102). Killing of tumor cells, at least in 
vitro, can be mediated by many different cell types. 
The tumoricidal activity of macrophages has been the 
object of a great deal of study. Mackannas defined 
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activation as: the enhancement, through immunologically 
specific reactions, of the immunologically non-specific 
capacity of macrophages to kill microbial pathogens 
(90). However, activation is often defined as the 
capacity of macrophages to mediate cytotoxicity towards 
tumor cells. Whether macrophages kill tumor cells in 
vivo as a mechanism of primary defense is still unknown. 
However, in vitro nearly all tumors are susceptible to 
macrophage cytotoxicity in a nonphagocytic, contact-
dependent process (90). The interaction between acti-
vated macrophages and target cells often leads to 
selective destruction of the neoplastic cell. It has 
been shown in vitro that layers of tumor cells will grow 
adjacent to but not in areas of macrophage growth, 
suggesting that cytolysis is restricted to the immediate 
vicinity of the macrophage (32,45,49). The mechanisms of 
tumor cell destruction by macrophages have been studied 
extensively (36,49), and may be affected by many types 
of secreted products such as enzymes, reactive oxygen 
intermediates, and secretory products. 
ROI are responsible for a great deal of candid-
acidal activity, however, the tumoricidal activity of 
ROI is not completely understood. Nathan has suggested 
that an oxidative mechanism may provide the means by 
which activated macrophages kill tumor cells (92). 
There is some evidence H202 is tumoricidal in vitro 
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(92). A possible role for myeloperoxidase in the 
killing of tumor cells by macrophages has also been 
suggested (18,104). However, it has been found that 
induction of tumoricidal function does not correlate 
with induction of the respiratory burst either as a 
matter of time or stage of macrophage activation (21) . 
Additionally, a majority of macrophage tumoricidal 
effects have been assigned to oxygen-independent 
mechanisms despite the observation that the toxic 
effects of macrophages toward target cells were signif-
icantly reduced when cells were cultured under anaerobic 
conditions (115). 
Extracellular secretion of proteins has been 
established as an important function of macrophages, 
suggesting the possibility that tumor cells may be 
destroyed by secreted products (2). Although primarily 
cytotoxic, these agents may serve to digest infectious 
agents which were killed by predominantly oxidative 
mechanisms (66). Possible mediators of macrophage 
oxygen-independent cytocidal activity include: acid 
hydrolases (2); alkaline phosphatase (30); arginase (4); 
and neutral proteases (1). Such secreted factors may 
play an important role in infectious agent destruction 
since killing of tumor cells normally precedes the 
degradative and destructive processes of phagocytosis 
( 2) • 
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Even in the absence of phagocytosis it is still 
possible that macrophages may transfer their lysosomal 
enzymes by a process of exocytosis (15). It has been 
shown that the content of secondary lysosomes are 
transferred to the tumor cell prior to cell lysis (48). 
Furthermore, it is known that lysosomal enzymes of 
activated macrophages mediate tumoricidal effects (48). 
The macrophage-tumor cell interaction is initiated by a 
recognition phase that results in polarization and 
eventual release of lysosomal constituents through 
macrophage exocytosis and membrane fusion (41). 
Lysosomes are transferred from activated macrophage to 
the cytoplasm of target cells (48,36). Biochemical 
changes which have been detected in the cell surface 
membrane of activated macrophages (e.g. 5'-nucleotidase) 
are similar to changes detected in the membranes of the 
phagosomes (66). Perhaps these or similar membrane 
changes are related to the capacity of the lysosomal 
membrane to fuse with the cell surface membrane prior to 
lysosomal exocytosis (35). 
Macrophages also secrete multiple components of 
the complement system, including constituents of both 
the classic and alternative pathways (2). Macrophage-
produced C3 can be cleaved into C3b, which activates 
macrophages to secrete hydrolytic enzymes, and C3a which 
is lytic for tumor cells (34). 
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Tumor necrosis factor (TNF) is a soluble molecule 
which may be involved in macrophage tumor cell killing 
(123). TNF is produced almost immediately following 
exposure to LPS and its production is dependent upon the 
continued presence of LPS (38). Exposure of macrophages 
to LPS results in the production of TNF (38). TNF 
itself is capable of lysing targets. Lymphotoxins or 
lymphocyte cytotoxic factors, are another set of 
macrophage cytotoxic products, which also directly lyse 
neoplastic cells (124). Lymphotoxins may be very 
similar or identical to TNF since studies have found 
that an anti-TNF antibody also removes the cytocidal 
activity of lymphotoxin (132). However, in short term 
assays only TNF is effective in tumor cell lysis, 
whereas both TNF and lymphotoxin are effective in long 
term assays (132). Many investigators appear to have 
isolated different cytotoxic factors. For example, 
different cytotoxic factors found in serum have differ-
ent stabilities at room temperature (122) and cytotoxic 
factors have varying sensitivity to heat treatments and 
proteases (124). One cytotoxic factor secreted from a 
macrophage hybridoma appears to be distinct from all 
other cytotoxic factors since it is heat stable and acid 
labile while others are not (121). Additionally, 
macrophage hybridomas have been produced which secrete 
cytotoxic factors and Interleukin-1 (IL-1) (122). 
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During infection, macrophages with bactericidal and 
tumoricidal activity display a parallel increase in IL-1 
and cytotoxic factor production (52). 
IL-1 is a central mediator in the regulation of 
the immune response. Macrophages are a major source of 
IL-1 and release it during the activation process. 
Regulation of IL-1 is itself complex. Low levels of TNF 
induce increased IL-1 production, while the converse is 
also true (52). However, these two are not direct 
mediators of one another, as high TNF levels induce PGE 
which blocks IL-1 production (52). 
The sensitivity of tumor cell lines to macrophage 
tumoricidal effects varies greatly and some tumor cells 
are even promoted to proliferation by macrophages (93). 
Completion of tumor cell lysis by macrophages requires 
direct binding to target cells (109). However, the 
glutathione oxidation-reduction cycle serves as a 
mechanism against oxidant injury, and accounts for 
varying susceptibility of tumor cells to oxidation (91). 
The sequence of events for macrophage killing of 
tumor cells may then be summarized in the following way: 
a)contact occurs between macrophages and target cells; 
b) lysosomal enzymes of macrophages are polarized toward 
bound tumor cells; c) spreading of macrophages at the 
tumor cell surface occurs; d) oxidative mechanisms are 
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released which weaken the tumor cell membrane; e) 
lysosomal constituents are released and tumor cells are 
lysed (2). 
c. Comparisons of extracellular killing 
It has yet to be determined whether increased 
tumoricidal and increased microbicidal activity are 
always generated together as a consequence of the 
activation process (96) • Some evidence exists which 
suggests that the two activities are separate (130). 
The possibility exists that macrophage activation occurs 
in a series of definite steps. This is indicated by the 
presence of one manifestation of activation occurring in 
the absence of others. The number of activation steps 
may be determined by the particular homeostatic func-
tions which the macrophage perform (96). For instance 
synthesis and secretion of plasminogen may require a 
definitive number of steps. Metabolic changes required 
for this action may occur earlier than or without 
acquisition and expression of the more complex function 
of increased microbicidal or tumoricidal activity (96). 
Whether populations of activated macrophages 
which display one functional activity also possess other 
functional capacities is not established (130) • 
Experiments have been conducted to measure the ability 
of macrophages to inhibit tumor cell DNA synthesis and 
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intracellular multiplication of Toxoplasma gondii (130). 
Macrophages removed from Toxoplasma spiralis infected 
animals after 19 weeks were able to inhibit tumor cell 
DNA synthesis yet were unable to prevent intracellular 
multiplication of T· gondii (130). Macrophages taken 
from the animals infected with T· gondii at 16 weeks and 
used immediately, inhibited DNA synthesis of tumor cells 
but failed to inhibit T· gondii intracellular replica-
tion (130). However, following incubation for 24 h in 
vitro, the capacity of these same 16 week macrophages to 
inhibit tumor cell DNA synthesis was lost while T· 
qondii intracellular replication was inhibited (130). 
These results suggest that the functions of activated 
macrophages in a given population maybe identical at any 
given time. However, the time of infection, the 
elicitation agent or immunization agent, and the time in 
culture, may alter the observed functional capacities of 
any given macrophage population. 
The functional differences in different macro-
phage populations which were observed by Wing (130) have 
also been observed by many other groups. Macrophages 
which express specific antitumor activity, or express 
antibacterial resistance, did not kill the intracellular 
organism Listeria (130). Therefore there is a clear 
dissociation of intracellular microbicidal activity from 
other macrophage functions (95,114). Conversely, it has 
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also been shown that host responses to intracellular 
infect:on results in an increased resistance to neopla-
sia (125). It Las been proposed that at maximum 
stimulation, all functional properties of activated 
macrophages may be expressed (130). The properties 
might be lost at different rates and consequently, at 
various times after activation only certain properties 
of activated macrophages are manifest. The functions of 
a given population must be considered with the number of 
factors already discussed which may induce variance 
(130). Alternatively, there may exist separate subpopu-
lations of macrophages which are activated differen-
tially and posses distinct functional capabilities 
(130). 
Mature macrophages from different sites may 
differ functionally depending on which function the 
macrophage is called upon to perform. One of these 
functions is the ability to kill. This functional 
heterogeneity in macrophage lineage is detectable at the 
precursor level (10). Bone marrow-derived macrophage 
precursors from CSF conditioned cultures possess the 
ability to kill, extracellularly, YAC-1, Candida 
albicans, and Leishmania (10). These nonadherent, 
nonphagocytic, macrophage precursors originate from 3 
day bone marrow liquid cultures. These cells are 
normally located in the bone marrow prior to recruitment 
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to peripheral organs (9). These macrophage precursors 
have been proven to possess an overall candidacidal 
potential greater than that expressed by resident 
macrophages (8). The same cells are also active against 
YAC-1 lymphoma cells (8). 
Bone marrow-derived macrophage precursors are 
able to mediate extracellular killing against tumor and 
fungi targets (8). Both of these activities are lost 
during the course of maturation to mature macrophages 
only to be regained later (8). For example, bone 
marrow-derived precursors can differentiate in the 
presence of CSF-1 which is deficient in interferon {IFN) 
to become resident macrophages. These mature bone 
marrow derived-macrophages are unable to kill Candida 
{8). The same cells when exposed to CSF-1 and IFN, can 
progress developmentally to a more differentiated state 
which has the capacity to kill {127). Upon activation, 
restoration of the cytocidal activity resumes in a 
process analogous to that observed for macrophages 
infiltrating an inflammatory site (127). The common 
precursors seem to lose or retain their activity 
depending on the environment of the anatomical site into 
which they migrate (8). 
Despite common mechanisms for the induction and 
expression of macrophage effector responses within the 
transient cytotoxic reaction, separate signals may 
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activate different functional capacities (89). Studies 
by Nacy (89), have shown that lymphokines from stimu-
lated spleen cells regulate cytotoxic reactions against 
various targets through different activation factors or 
lymphokines. For instance factors added from cultures 
of murine spleen cells induce microbicidal activities 
against the intracellular targets Rickettsia tsu-
tsugamushi or Leishmania tropica. These same factors 
are completely ineffective for inducing cytocidal 
activity against extracellular targets such as tumor 
cells or Schistosoma mansoni (89). Furthermore, 
lymphokines which induce intracellular killing can be 
separated into three components or factors. The 
extracellular killing is induced by only one factor, 
separate from the factors which induce intracellular 
killing (89). If a population of the T-cell lymphoma 
EL-4FARRAR is stimulated with PMA, extracellular killing 
and intracellular killing were found to be exclusive 
(89). In this situation, lymphokines were found to 
contain two components which induced extracellular 
killing, whereas only one lymphokine component was found 
to induce intracellular killing. The component which 
induced intracellular killing appeared to be identical 
to one of the extracellular components (89). These data 
suggest that induction of an effector response is 
dependent upon specific activation factors. It is clear 
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that macrophage activation for cytotoxicity against 
tumor and schistosomula targets is coincident over a 
broad range of experimental conditions (59). Both 
resident and elicited macrophages can be activated to 
this parallel activity (59). Whether the mechanisms of 
macrophage cytocidal tumoricidal and schistosomulacidal 
activity induced by these lymphokines are similar 
remains to be clarified (58). Both cytocidal activities 
were induced by the same large molecular weight activat-
ing factors suggesting that identical effector function 
originates from the same activating signal (89). The 
identiy of these lymphokines is unknown. Whether the 
lymphokine activities are from unrelated molecules or 
aggregates of a single molecule also is unknown. What is 
most important is that macrophage cytocidal activity 
against two divergent extracellular targets, tumor cells 
and helminthic worms were induced by the same macrophage 
activating lymphokines (89). Equally important was the 
observation that cytocidal activity against two totally 
unrelated intracellular parasites that reside in 
different compartments (intracytoplasmic rickettsiae and 
intraphagolysosomal leishmania) was induced by a common 
mechanism (89). The extracellular cryptococidal and 
tumoricidal results of Granger closely parallel the 
cytostatic effects noted above (42). In fact, the 
kinetics of onset and the effector cell sensitivity to 
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LPS, again indicate a similar mechanism of activation 
( 4 2) • 
It appears clear that regulation of macrophage 
cytotoxicity is controlled by qualitatively different 
factors (89) . One which controls extracellular targets, 
another, which controls intracellular cytotoxicity (89). 
The cytocidal activities of macrophages are 
influenced by many factors, including the level of 
activation of the macrophage. The capacity of macro-
phages to respond to stimuli and induce a functional 
response, such as extracellular killing, has been 
studied extensively (89). In comparisons of extra-
cellular killing of schistosomes and tumor cells, 
cytocidal effects were found to take place upon activa-
tion with particular lyrnphokines (90). The activation 
of macrophages with LPS has shown similar results. 
Nonactivated states, (resident and elicited) displayed 
parallel tumoricidal and schistosomicidal activity, 
again emphasizing similar levels of activation for 
extracellular cytocidal activity. 
In contrast, little work has been done c~mparing 
the candidacidal and tumoricidal effects of macrophages. 
Most studies of Candida have been performed with the 
yeast phase of the fungus which is phagocytosed and 
killed in an intracellular manner (108). Based on 
studies by Nacy et .sU:.., comparing differential activa-
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tion of macrophages by certain activating factors for 
intracellular cytocidal activity as compared to activat-
ing factors which induce extracellular cytocidal 
activity (89), one would not expect to find similar 
levels of activity for the intracellular killing of 
phagocytozed Candida as compared to the extracellular 
killing of tumor cells. Instead it would be expected 
that the intracellular killing of phagocytosed Candida 
would be mediated by different activation mechanisms and 
different cytocidal mechanisms than that of the hyphal 
form of Candida which must be killed in an extracellular 
manner. The possibility exists that similar activation 
mechanisms for cytocidal activity would be demonstrated. 
However based on the wide differences encountered by the 
macrophages in comparing these two targets the possibil-
ity is unlikely. More likely is a separate and distinct 
activation mechanism for extracellular killing and 
intracellular killing. 
Work on macrophage precursors has indicated that, 
in a nonphagocytic manner, these cells have the ability 
to kill Candida, Leishmania, and tumor cells. That 
study utilized the yeast phase of Candida, relying on 
the inability of the macrophage precursor to phagocytize 
for studies of extracellular killing (8) rather than 
studying the mature macrophage and its extracellular 
killing mechanisms. 
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No studies have been completed comparing the 
cytocidal effects of macrophages on Candida in the 
hyphal form to the cytocidal effects of macrophages on 
tumor cells. Furthermore, no study has been undertaken 
to evaluate the relative cytocidal capacities of 
macrophages at various levels of activation. This study 
compares the levels of candidacidal and tumoricidal 
activity of macrophages at set levels of activation. 
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CHAPTER III 
MATERIALS AND METHODS 
A. Tumor Cell Line. 
The EL-4 lymphoma (40) was obtained from R. 
Herberman, National Cancer Institute, Bethesda, 
Maryland. EL-4 cells were maintained in vitro in 
corning 25 cm2 tissue culture flasks (Corning, NY) 
containing RPMI 1640 (Gibco, Grand Island, NY) supp-
lemented with 10% fetal bovine serum (FBS) (low LPS) 
(Gibco, Grand Island, NY) penicillin 100 units/ml, 
streptomycin 100 µg/ml, and Fungizone (PSF) (Whittaker, 
Walkersville, MD) 0.25 µg/ml, and 2mM L-glutamine 
(Gibco, Grand Island, NY). Cells were passaged 3 times 
weekly with maximal concentration not exceeding l x 
106/ml. 
B. Radiolabelling of EL-4 Tumor Cells. 
Tumor cells maintained in vitro were washed once 
in culture medium and resuspended to 2 to 5 x 106 
cells/ml. The cells were subjected to centrifugation at 
soo x g for 10 min, decanted, and the pellet resuspended 
in approximately 0.1 ml of culture medium. Then 100 
µCi/ml of Na25lcro4 (New England Nuclear, Boston, 
MA) was added to approximately 1 x 107 cells in a final 
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volume of 0.2 ml. These cells were incubated at 37°c 
with 5% co2 for 1 h with frequent agitation (every 10 
min). The cells were then washed four times in HBSS, 
resuspended to 1 x 106 cells/ml in culture medium and 
0.01 ml aliquoted to each well of a 96 well assay plate 
(Falcon 3072, Oxnard, CA) {27,129). 
c. Fungal Culture 
Candida albicans ATCC 58716 obtained from T. 
Hashimoto, (Loyola University Medical Center, Maywood, 
IL) was used throughout this investigation. Cultures 
were stored at 25°c on Sabouraud Dextrose Agar (SDA) 
(Becton Dickinson and Co., Cockeysville, MD). Cells 
used for experimentation were cultured overnight at 37oc 
on SDA, collected as isolated colonies, and washed once 
in HBSS prior to inoculation into Dulbecco's modified 
Eagle medium {DMEM, 4.5 g/L glucose) {Whittaker, 
Walkersville, MD). Any culture with greater than 15% 
budding cells was discarded. Candida hyphal forms were 
obtained by incubation at 37°c in DMEM. The inoculum of 
1 x 105 Candida yeast cells/ml yielded approximately 
100% hyphal fragments ranging in length from 40-65 µm 
when incubated for 3 hat 37°c {46). 
D. Preparation of Macrophage Elicitation Agents. 
Proteose peptone broth No. 3 {Difeo Laboratories, 
Inc., Detroit, MI) was prepared as a 10% sterile 
solution. Aliquots were placed in 5 ml batches and 
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frozen at -20°c until needed. Brewer Thioglycollate 
Medium (Difeo Laboratories, Inc., Detroit, MI) used for 
intraperitoneal injections of mice was prepared as 
described previously (16,74). An autoclaved solution 
was allowed to become oxidized for six months in storage 
at room temperature. The media was distributed in 5 ml 
aliquots and frozen at -20°c for later use. 
E. LPS Preparation. 
LPS from Salmonella typhosa 0901 was purchased 
from Difeo Laboratories, Inc., (Detroit, MI), in 
lyophilized form. After rehydration, the LPS was 
distributed into 1 ml aliquots at a concentration of 500 
µg/ml and stored frozen at -20°c until needed (16). 
F. Macrophages 
Female C57Bl/6 mice (Jackson Labs, Bar Harbor, 
ME), 8-16 weeks of age, were injected intraperitoneally 
with 1 ml of freshly prepared proteose peptone broth or 
1 ml of aged thioglycollate broth. After 4 days, the 
mice were sacrificed by cervical dislocation and the 
peritoneal exudate cells (PECs) removed by lavage with 
10 ml of HBSS (74). The PECs were also removed from 
normal mice which were not injected with proteose 
peptone or thioglycollate. The PECs were washed twice 
in HBSS and resuspended in RPMI-1640, supplemented with 
10% FBS, (Gibco, Grand Island, NY), penicillin 100 
µg/ml, streptomycin (Whittaker, Walkersville, MD) 100 
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ug/ml, and 2mM L-glutamine (Gibco, Grand Island, NY). 
Fungizone was omitted from the medium. These PECs were 
then allowed to adhere as described below to plastic 
culture vessels, either 24 or 96 well plates (Falcon 
3047 or 3072, Oxnard CA). The non-adherent cells were 
removed by withdrawing the medium and gently flushing 
once with fresh culture medium which was immediately 
removed. Viability was routinely determined by 0.04% 
trypan blue exclusion. 
G. Macrophage Activation. 
The groups of macrophages evaluated by this study 
were; I= Resident, II= Induced, III= Activated, and IV= 
Post-Activated (82). Group I macrophages were obtained 
from the peritoneal cavity of naive mice (27). Mice for 
groups II - IV were injected four days previously with 
10% proteose peptone broth. Group II were proteose 
peptone-induced macrophages with no in vitro treatment. 
Group III were macrophages activated in vitro with LPS 
(10 µg/ml) for 18 h. Group IV were macrophages which 
were cultured in vitro with LPS (10 µg/ml) for 72 h. 
Mice injected with thioglycollate broth four days 
previously were termed group IIt-IVt and were treated as 
described above for proteose peptone-elicited macrophage 
states II-IV. Additionally, some group I macrophages 
were treated in vitro with LPS (10 µg/ml) for either 18 
h or 72 h and were termed group IIIr or group IVr, 
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respectively. 
H. Tumor Cytotoxicity Assay. 
The methods employed for this assay are modifi-
cations of the procedure originally described by Doe and 
Hansen (16,27). PECs used for tumor cytotoxicity assays 
were placed in 96-well plates (Falcon 3072, Oxnard, CA) 
at 2 x 105 PECs/well. Two h later the non-adherent 
cells were removed by aspiration of the media and 
replacement with fresh culture medium (0.2 ml). The 
wells were approximately 70-80% confluent with macro-
phages for all groups. Following an additional 20-24 h 
of incubation at 37°c, nonadherent cells were removed 
and fresh medium added. These adherent PECs are 
referred to as macrophages. At this time, LPS was added 
in a final concentration of 10 µg/ml to each well for 
groups III and IV. After 18 h of incubation for groups 
I-III and 72 h of incubation for group IV, 1 x 104 
labelled tumor cells were added to each well in a 0.01 
ml volume. Following an additional 18-24 h, the plates 
were subjected to centrifugation for 5 min at 200 x g, 
100 µl of the supernatant fluid was removed from the 0.2 
ml volume contained in each well, and assessed for 
radioactivity by use of an automated gamma counter 
{Beckman, Gamma 4000, Irving, CA). Maximum release was 
obtained by adding 0.5% Nonident P-40 {Sigma Chemical 
Co., St. Louis, MO) to wells containing media and 
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macrophages without LPS. 
Data for this assay was based on a 20:1 effector/target 
ratio and results are expressed as % cytotoxicity as 
judged by release of Slcr. 
% cytotoxicity = 
(mean experimental DPM) - Cmean minimum DPM) xlOO. 
(mean maximum DPM) - (mean minimum DPM) 
Results are expressed as the mean of triplicate cultures 
from four separate experiments. 
I. Candida Cytotoxicity Assay. 
Candidacidal activity of macrophages was quant-
ified by the microcolony method of Hashimoto (46). This 
method takes advantage of the dimorphic nature of 
Candida. PECs were placed in 24-well plates (Falcon 
3047, Oxnard, CA) at 1 x io6 cells/well, with a 12 mm 
circular cover slip (no. 1: Rochester Scientific co. 
Inc., Rochester, NY) within each well. PECs were 
treated and activated as described above for the 
tumoricidal assay except, that culture medium was 
removed.and the macrophages gently washed to remove 
fungizone prior to the addition of Candida in DMEM. The 
viability of individual ~. albicans hyphae recovered 
from the culture wells was determined as follows: non-
phagocytosable Candida hyphae were exposed to macro-
phages at an effector/target ratio of 10:1, and incu-
bated on the surface of cover glasses placed in the 
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bottom of a well of a 24 well cluster plate for 1 h. 
The DMEM was removed. Sabauroud's dextrose broth 
containing 0.5% Nonident P-40 (Sigma Co. St. Louis, 
MO) was added to each of the wells. The cover slips were 
recovered from the wells, gently rinsed in Sabauroud's 
dextrose broth without Nonident P-40, and placed 
inverted on a slide containing a thin layer of SDA (10 
mm thick). This procedure only partially lyses the 
macrophage membrane allowing essentially all of the 
Candida hyphae to adhere to the glass surface via 
remnants of the macrophage membrane. The microculture 
was incubated under conditions conducive to the yeast 
phase of growth at 37°c for 5 h in a moist chamber. The 
cultures were examined with a phase contrast micro-
scope. Routinely, 200 hyphae were examined for each 
sample, and the percentage of nonviable hyphae in each 
sample calculated. Results are expressed as the mean of 
triplicate cultures and four separate experiments. 
J. Statistics 
The Student's t test was used to determine the 
statistical significance of results. 
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CHAPTER IV 
RESULTS 
Four different groups of macrophages were 
compared for their tumoricidal and candidacidal activi-
ties. Results which compare the tumoricidal activity of 
the four groups of macrophages are presented in Fig. 1. 
Compared to group I (resident macrophages), a signifi-
cant increase in cytotoxic activity was observed for 
groups II (macrophages elicited from the peritoneal 
cavity with protease peptone) and III (proteose peptone-
elicited macrophages activated in vitro with LPS (10 
µg/ml) for 18 h), while a significant decrease was 
observed for group IV (protease peptone-elicited 
macrophagess incubated in vitro for 72 h with LPS (10 
µg/rnl). The cytotoxic activity of group I macrophages 
at 40.5% ± 0.7% release was exceeded by group II at 
45.2% ± 0.6% release (p<0.001). Group III showed the 
greatest tumoricidal activity at 53.8% ± 1.5% release 
(p<0.001) when compared to group I. However, macrophages 
stimulated with LPS for 72 h (group IV) showed a 
significant decrease (p<0.001) in cytotoxic activity to 
29.7% ± 0.7%, when compared to group I macrophages. A 
significant increase (p<0.001) in cytotoxic activity was 
observed between group III (53.8% ± 1.5% release) and 
group II (45.2% ± 0.6% release). There was no signifi-
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Figure 1. 
comparison of macrophage groups as judged by 18 h 5lcr 
release assay. Values are displayed as mean of 4 
experiments performed in triplicate. Bars indicate ± 
standard deviation (SD). Macrophage populations are 
as follows; group I (resident macrophages), group II 
(proteose peptone-elicited macrophages), group III 
and group IV were proteose peptone-elicited and either 
treated with LPS for 18 h (group III), or treated with 
LPS for 72 h (group IV). Groups II and III are 
significantly (p<0.001) higher than group I, while 
group IV is significantly (p<0.001) lower than group 
I. Group II is significantly lower than group III 
(p<O. 001). 
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Resident Elicited Activated Activated 
(18h) (72h) 
Macrophage Group 
cant difference in cytotoxicity between group I resident 
macrophages cultured for 72 h without LPS stimulation 
and group I (data not shown). 
As a comparison, macrophages from group I were 
exposed to LPS (10 µg/ml) in vitro for 18 h or 72 h. 
See Table 2. These macrophage groups were termed group 
III resident (IIIr) and group IV resident (IVr), 
respectivly. Cytotoxixicty by macrophages from group 
IIIr (54.8% ± 1.7% release) was not significantly 
different in tumoricidal activity from the experimental 
group III (53.8% ± 1.5 % release). Group IIIr was 
significantly more cytotoxic than either group II 
(p<0.001) or group I (p<0.001). Group IVr (31.3% ± 
1.8%) displayed a significantly lower level of cytotoxic 
activity then group I while displaying no difference 
with regard to group IV. 
In an identical series of experiments, macrophages 
were thioglycollate-elicited (group IIt), or thioglycol-
late-elicited and treated with either LPS (10 µg/ml) for 
18 h (group IIIt), or LPS (10 µg/ml) for 72 h (group 
IVt). Tumoricidal activity of the group IIt macrophages 
(51.7% ± 1.7% release) showed a significant increase 
(p < 0.001) from both group I (40.5% ± 0.7% release) 
and group II (45.2% ± 0.6% release). There was no 
difference between group IIt and group III. Group IIIt 
showed a significant increase from group III (p<0.05) 
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Table 2. Comparison of treatment groups as judged 
by the extracellular tumoricidal assay. 
Group Resident 
Number 
I 40.5±o.7c 
II _d 
III 
IV 
Cytotoxicity 
Eliciting Agent 
Proteose 
Pe pt one 
45.2±0.6 
53. 8±1. 5 
29.7±0.7 
None 
(r)a 
54. 8±1. 7 
31.3±1.8 
Thioglycollate 
(t)b 
51. 7±1. 7 
57.6±1.9 
25.5±2.2 
aResident macrophages (r) activated with LPS. 
bThioglycollate (t)-elicited macrophages. 
Coata expressed as the mean of 4 experiments performed 
in triplicate ± SD. Groups II-IV (including all 
resident activated; IIIr and IVr, and thioglycollate; 
IIt, IIIt, and IVt) displayed a significance of 
p < 0.001 when compared to group I. Additionally, 
groups IIt, III, IIIt, and IIIr displayed a significant 
increase (p< 0.001) to group II. 
dExperimental values not determined due to protocol. 
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producing the highest level of cytotoxicity. Group IVt 
macrophages (25.5% ± 2.2% release) showed a signifi-
cantly lower (p<0.001) level of tumoricidal activity as 
compared to those in group I. Additionally, group IVt 
(25.5% ± 2.2% release) was significantly (p<0.05) less 
cytotoxic than both normal group IV (29.7% ± 0.7% 
release) and resident group IVr (31.3% ± 1.8% release). 
Simultaneously, candidacidal activity was measured 
with identical macrophage populations. Results are 
expressed as % cytotoxicity, defined as that part of the 
culture able to return to the yeast phase from the 
hyphal phase following a 1 h exposure to the macrophage 
populations. These studies showed that the level of 
candidacidal activity paralleled that of the tumoricidal 
assay. See Figure 2. The data show group I macrophage 
activity which resulted in Candida cytotoxicity of 
22.2% ± 3.0%. This differed significantly from the 
34.5% ± 2.9% cytotoxicity observed following exposure to 
group II macrophages (p<0.001). Treatment with LPS for 
18 h (group III), significantly increased the can-
didacidal activity of these macrophages to 46.0% ± 3.9% 
cytotoxicity (p<0.001). Group II macrophages resulted 
in Candida cytotoxicity of 34.5% ± 2.9% which was 
significantly lower (p<0.001) than the cytotoxicity 
(46.0% ± 3.9%} observed with group III macrophages. 
However, unlike the tumoricidal results, there was no 
52 
53 
Figure 2. 
Comparison of macrophage groups as judged by the 
extracellular candidacidal assay. Values are 
displayed as mean of 4 experiments in triplicate. 
Bars indicate ± SD. Groups are described in the 
legend to Figure l. Results are expressed as % 
cytotoxici ty for Candida after l h exposure to the 
various macrophage populations (* = p < 0.001 to group 
I,+= p < 0.001 to group II). 
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Resident Elicited Activated Activated 
(18h) (72h) 
Macrophage Group 
statistical difference between the cytotoxicity result-
ing after treatment with either group I or group IV 
macrophages. 
No appreciable differences were found between 
macrophage candidacidal activity of either group IIIr 
and group IVr or group III and group IV, respectively 
(Table 3). In the candidacidal assay, group IIt 
macrophages produced a much higher cytotoxicity (43.2% ± 
3.2%, p<0.001) when compared to group I macrophages 
(22.2% ± 3.0%). The cytotoxicity resulting after 
incubation with group IIt macrophages was significantly 
higher than that with group IIIt macrophages (47.1% ± 
2.7%, p < 0.001). However, no difference in cytotoxi-
city following exposure to macrophages of group IIt 
(43.2% ± 3.2%) and group III (46.0% ± 3.9%) or group 
IIIr (40.2% ± 4.2%) was observed. 
55 
Table 3. Comparison of treatment groups as judged 
by the extracellular candidacidal assay. 
Cytotoxicity 
Eliciting Agent 
Group Resident Proteose None Thioglycollate 
Number Peptone (r)a (t) 
I 22.2±3.0 b 
II _j 34.5±2.9d 43.2±3.2d,i 
III 46.0±3.9d,i 40.2±4.2d,g 47.1±2,7d,i 
IV 24.5±5.2e,h 17.7±2.7e,i 27.0±3,7c,f 
aResident macrophages activated with LPS. See footnotes 
of Table 2 for abbreviations. 
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boata expressed as the mean of 4 experiments perf.ormed in 
triplicate ± SD. Following notations denote significant 
differences from stage I 
c = p < 0.05 to stage I 
d = p < 0.001 to stage I 
e = p > 0.05 N.S. 
Following notations denote significant differences from 
stage II 
f = p < 0.05 to stage II 
g = p < 0.02 to stage II 
h = p < 0.005 to stage II 
i = p < 0.001 to stage II 
jExperimental values not determined due to protocol. 
CHAPTER V 
DISCUSSION 
It has been speculated that the mechanisms of 
extracellular, non-specific, macrophage-mediated cyto-
toxicity are the same for any target (59). The results 
of this investigation indicate that the extracellular 
cytotoxic activity of macrophages for two distinctly 
different targets appears to be similar and to be 
coincidentally expressed. Parallel levels of extra-
cellular macrophage cytotoxicity for both schistosomula 
and tumor cells have been demonstrated previously (67). 
The cytotoxicity was found to be coincident regardless 
of the method of macrophage treatment (59,67). In 
contrast, it has been noted that despite common mech-
anisms of macrophage induction and expression, the 
observed macrophage effector functions may be variable 
(88). Killing of the yeast form of ~. albicans by 
peritoneal exudate cells, does not correlate with tumor 
cytotoxic activity (13). Other comparisons of activated 
macrophages have shown that extracellular tumoricidal 
activity did not correlate with intracellular candid-
acidal activity (114). Macrophage activating factors 
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which induced macrophage extracellular tumoricidal and 
schistosomulicidal activity have been shown to differ 
from factors which induce intracellular microbicidal 
activity (89). 
The results of this investigation show that the 
capabilities of resident (group I), proteose peptone-
elicited (group II), proteose peptone-elicited and LPS 
activated for 18 h (group III), and proteose peptone-
elicited and LPS activated for 72 h (group IV) macro-
phages to be cytotoxic to Candida albicans paralleled 
their capacity to be cytotoxic to a cultured cell line, 
the EL-4 thymoma. 
Resident macrophages placed in culture for 18 h 
were found to possess both extracellular fungicidal and 
tumoricidal activity. Previously published work has 
shown resident macrophage populations to be at a basal 
level of activation (82,128). In those experiments, 
resident macrophages were defined as cells derived from 
the peritoneal cavity of mice and immediately employed 
for cytotoxic activity against an extracellular target 
(128). In contrast, in this investigation macrophages 
were cultured for 18 h prior to assessment of macrophage 
predicted cytotoxicity. Under these conditions, 
resident macrophages do have the ability to kill both 
fungi and tumor cells in an extracellular manner. 
Likewise, the tumoricidal assay showed levels of 
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resident macrophage activity which were higher than that 
which has been reported previously (105). This may be 
attributed to variations in target type, mouse strain, 
macrophage concentration, or the LPS employed. However, 
it is more probable that the relative activity of the 
macrophages cultured for 18 h prior to onset of the 
activation process have an enhanced cytotoxic activity. 
During the 18 h culture period, macrophages were 
adherent to plastic culture vessels and possibly exposed 
to small amounts of contaminating LPS contained within 
the serum of the media. Weinberg has shown LPS contami-
nation of media culture products leads to a more 
activated macrophage state (128). Therefore, the 
definition of resident macrophages in this study does 
not necessarily equate with macrophage populations 
termed "resident" in other studies (27,105). The 18 h 
period of incubation was necessitated by the experi-
mental design in that a simultaneous time course for all 
experiments was vital for comparative purposes. 
l.n vitro, resident macrophages may be induced to 
the activated state by simulating conditions in vivo. 
For example, resident macrophages may be primed by an 
antigenic stimulus resulting in the release of lympho-
kines. such a stimulus could serve as an eliciting 
agent, which has been reported previously to produce 
enhanced cytocidal effects (54). Macrophages induced by 
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sterile irritants have been shown to be potentially 
capable of cytolytic activity, if noncytolytic but 
"receptive" monocytes were present (103). Proteose 
peptone-elicited macrophages (group II) from both the 
tumoricidal and fungicidal assays displayed a parallel 
increase in the extracellular killing of both targets. 
A significant increase such as the one demonstrated here 
does not agree with previous work which has demonstrated 
proteose-peptone elicited macrophages do not reach a 
level of macrophage activation which results in microbi-
cidal or tumoricidal activity (128). In those investi-
gations, macrophages were removed from the peritoneum 
and utilized immediately (128). Macrophages used in 
experiments here were allowed to remain in culture for 
18 h prior to the activation required for group III 
macrophages. Therefore, a total time of 36 h elapsed 
prior to evaluation of cytocidal activity. This 
treatment was identical to treatment received by group I 
or resident macrophages which also resulted in higher 
than expected cytocidal activity. Nevertheless, at a 
level of p<0.001 parallel differences have been found in 
each of the assays. These results indicate an increased 
cytocidal activity for the overall population of 
cultured macrophages. 
When macrophages were treated with LPS (lOµg/ml) 
for 18 h (group III), maximum tumoricidal and fungicidal 
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activity was found for both assays. The parallel 
increase in functional cytocidal activity was apparent. 
This is consistent with previous reports which show that 
LPS can induce cytotoxicity by macrophages which are 
already partly activated to maximum activity without 
lymphokines (16,128). To become cytocidal, less 
activated cells require large doses (lOµg/ml) of LPS 
(16). Unactivated (resident) cells have been found to 
vary in this response (16). However this study has 
shown that resident macrophages do obtain cytocidal 
activity when treated with large doses of LPS. Group 
III macrophages were also observed to show an enhanced 
level of activity over group II macrophages in both 
systems. Again, these results suggest parallel levels 
of fungicidal and tumoricidal activity by the macrophage 
population. The parallel increases in cytotoxic 
activity suggest the cytocidal effect to be non-specific 
in nature. That is, the mechanisms employed appear to 
be capable of lysing diverse targets. 
The one observed difference in which the relative 
tumoricidal and fungicidal activity did not parallel 
each other, was with group IV macrophages. It was 
expected that macrophages which had been maximally 
activated would return to a level of cytocidal activity 
at or near the unactivated or resident macrophage (2). 
Group IV macrophages did return to a level of fungicidal 
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activity which was not significantly different from 
resident or group I macrophages. However, the tumor-
icidal activity of group IV macrophages dropped to a 
level significantly below that of the resident macro-
phages. This may be attributed to the length of the 
tumoricidal Slcr release assay in that the macrophages 
were exposed to 10 µg/ml of LPS for 96 h. The respon-
sive capability of the macrophages may have been 
overwhelmed by this continued stimulation. This is 
further supported by the observation that cultures of 
group I and group II macrophages which were not acti-
vated with LPS, but were simply cultured for 72 h, 
demonstrated a level of activity near group I for both 
the tumoricidal and fungicidal assays. The observation 
of a reduction in cytocidal activity provides a possi-
bility that the macrophage may be a self-regulating 
population. The cells may produce a signal which 
operates in a manner similar to the process of activa-
tion. This regulatory product may be an arachidonic 
acid metabolite, such as prostaglandin E, which has been 
shown to down-regulate macrophage functional capacity by 
limiting expression of tumor cytolysis and certain 
other macrophage capacities. The suppressive effect may 
also be a result of tolerance to the original stimula-
tory signal. Clearly, a reduced response was observed. 
Whether the effect is a consequence of a metabolite 
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blocking a terminally differentiated or tolerant cell or 
simply a cell which has returned to its basal level of 
activity remains to be demonstrated. Nevertheless, both 
assay systems displayed significant decreases in 
cytotoxicity from groups II and III to group IV. In 
this respect parallel killing was observed for all four 
groups of macrophages. 
When activated with LPS, thioglycollate-elicited 
macrophages displayed the highest levels of cytocidal 
activity in both assays. Thioglycollate-elicited 
macrophages displayed, in both the tumoricidal and 
fungicidal assays, an enhanced cytotoxic activity 
greater than that of macrophages elicited with proteose 
peptone. Thioglycollate broth is often used as an 
eliciting agent because it has the advantage of recrui-
ting large numbers of cells to the site of inflammation 
(117). However, the microbicidal activity of these 
macrophages is variable, indicating the macrophages may 
not be totally activated (85). In contrast to previous 
studies which place thioglycollate-elicited macrophages 
into a functionally resident or primed classification 
(54,74), experimental evidence here indicates that 
thioglycollate-elicited macrophages may be in an 
activated state. There was no difference between these 
macrophages and protease peptone-elicited macrophages 
activated with LPS. These results may be the conse-
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quence of enhanced activation in vivo or as in the case 
of group I and group II macrophages, a higher level of 
activity induced during the activation period in vitro. 
Miake has proposed that functional activities of 
macrophage populations vary dependent upon the elici-
tation agent employed (85). Miake further stated that 
macrophage populations may have different levels of 
cytocidal activity or activation. The results of this 
study have shown similar variability. Proteose peptone 
and thioglycollate broth both elicited macrophage 
populations which displayed significantly different 
tumoricidal and candidalcidal activity. Upon activation 
with LPS both of these populations displayed levels of 
activation which differed, indicating that levels of 
activation are dependent upon the elicitating agent and 
the activation signal. 
Variable cytocidal activities have been reported 
for thioglycollate-elicited macrophages (16,61,90). 
Russell has shown that thioglycollate-elicited macro-
phages exposed to pg/ml concentrations of LPS will 
activate macrophages for tumoricidal activity, which is 
consistent with the study performed herein (105). 
Additionally, Russell has shown that thioglycollate-
elicited macrophages do possess tumoricidal activity 
without stimulation of LPS. Other groups have reported 
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different findings (27,49). Any number of factors may 
contribute to this discrepancy. It has been proposed 
that enhanced macrophage cytocidal activity of thiogly-
collate-elicited macrophages may be the result of 
macrophage activation due to LPS-contamination (105). 
Additionally, the cytocidal response of thioglycollate-
elicited macrophages has been shown to vary depending on 
the particular batch of thioglycollate utilized. 
Campbell (16) has demonstrated that Brewer's thioglycol-
late medium which was allowed to oxidize, produced 
macrophages which had enhanced cytocidal activity when 
cultured with LPS. The thioglycollate used in these 
experiments was allowed to oxidize for at least 6 months 
at room temperature prior to elicitation process. 
Many other points of variability exist when 
considering elicitation with thioglycollate, including 
the observation that varying levels of LPS concentra-
tions have also been shown to be required for activation 
of these cells to a cytocidal state (16). However, 
the high levels of LPS utilized in this study should 
allow for maximum activation. The age of the mouse may 
also vary the activation level of thioglycollate-
elicited macrophages. Hopper has shown no difference in 
the number of macrophages elicited from the peritoneum 
of mice from various eliciting agents at 6-8 week (54). 
However, older mice display a different pattern of· 
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macrophage inflammation and activity, thus displaying 
more variability. Therefore, variations in the ages of 
mice employed in previous studies may have resulted in 
variable cytocidal effects (54). 
Bone marrow-derived macrophages have been described 
as a precursor cell which matures through the monocyte 
maturation pathway to become a fully functional macro-
phage (127). Previous investigators have shown bone 
marrow-derived macrophages, upon activation, become 
tumoricidal (127). If bone marrow-derived macrophages 
are driven to maturation prior to establishment of a 
resident state, they possess a variety of extracellular 
cytocidal activities against such targets as the yeast 
form of both Candida, Cryptococcus, Leishmania, and 
tumor cells (10). 
It was the purpose of this investigation to 
evaluate the maturation sequence of bone marrow-derived 
macrophages after two weeks of in vitro cell culture. 
Macrophages which were allowed to remain in culture 
without the addition of LPS displayed levels of candida-
cidal activity which were not significantly different 
from resident macrophages. The candidacidal activity 
was slightly higher, and could result from the length of 
culture required to achieve maturation. 
Identically treated bone marrow-derived macrophages 
were pulsed with 10 µg/ml of LPS 18 h prior to evalu-
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ation of candidacidal activity. This group of macro-
phages obtained levels of activity similar to that of 
group II macrophages. There were significant differ-
ences between these macrophages and peritonital macro-
phages activated with LPS. It is possible that the bone 
marrow-derived macrophages activated with LPS are in a 
state of activation either between groups II and III or 
between groups III and IV. The 18 h activation period 
employed may have been inadequate and henceforth, would 
not allow sufficient time for proper activation to full 
cytotoxicity. Alternatively, LPS stimulation may have 
been either too strong or too delayed following stimu-
lation. Either of these would result in the downregu-
lation of function and place the macrophages into a 
level of cytocidal activity between groups III and IV. 
The tumoricidal activity of the macrophage groups 
correlate with previous attempts to define discrete 
stages of macrophage activation. The terminology of 
resident, primed, and activated have been used to 
describe levels of activation with regard to tumoricidal 
activity (43). The methodology and treatment of the 
macrophages in these experiments was similar to the 
procedure employed in this investigation. Other stages 
of activation have been proposed, such as inflammatory 
(60) and responsive (61). However, these stages are 
difficult to evaluate because they are activated with 
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lymphokines and furthermore they are defined by appear-
ance of certain receptors such as C3 and 5'-nucleotidase 
(61). These stages may indeed be apparent. However, 
the comparison of functional cytocidal activity versus 
the appearance of cellular maturation markers has not 
been made. 
The regulation process of macrophage activation for 
functional activity is complex. Comparisons of func-
tional activities must consider various aspects of the 
assays used to measure functions including: the origin 
of the responding cell, the activation signal, the 
susceptibility of the target to the macrophage, and 
nuances associated with the assessment of macrophage 
function (81). In this study these parameters have been 
addressed. An inbred strain of mouse was used to obtain 
the groups of macrophages. The macrophages were treated 
in an identical manner from elicitation through lavage 
to activation, both throughout the study and within each 
experiment. The macrophages were treated together until 
separated for the assays, at which point treatments 
received were identical. The same level of LPS was 
employed for all experiments (lOµg/ml). This was based 
on work by Weinburger which showed LPS at 10 µg/ml to be 
effective in activating macrophages to tumoricidal 
activity. Additionally, in vitro experiments have shown 
LPS to stimulate macrophages to kill Candida at lOµg/ml 
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(98). Furthermore, both targets have been shown 
previously to be susceptible to the cytotoxic effects of 
macrophages. 
Other considerations must be made regarding these 
assays such as the nature and concentrations of both the 
target and effector cells. Adherent peritoneal exudate 
cells have been defined in this study as macrophages. 
This definition implies only that non-adherent cells 
were removed from the culture and does not absolutely 
exclude the possibility that a small number of residual 
non-adherent cells may remain which either directly or 
indirectly influence the cytotoxic response of the 
macrophages. Campbell has shown that PECs were equally 
cytotoxic whether removed by simple washing techniques 
such as those employed herein, or by multiple vigorous 
washings. Additionally, if excess non-adherent spleen 
cells were added to the culture wells, no increase in 
cytotoxicity was noted (16). Furthermore, macrophages 
must be placed in culture, such that a less than 
confluent monolayer of cells results (16,99). This is 
important for two reasons. First, if the concentration 
is too high, macrophages tend to round up and spread 
poorly, resulting in inhibition of macrophage function. 
Second, if the macrophages are too scarce in the culture 
vessel, the cells fail to produce optimal cytocidal 
activity. This study utilized macrophage concentrations 
69 
similar to those employed by Cambell for the tumoricidal 
assay. Likewise, the concentration of macrophages used 
for the candidacidal assay was recommended by the author 
of the assay to provide a monolayer (46). 
While some of the problems associated with each 
assay can be regulated, others cannot be as stringently 
controlled. For example, macrophage cytotoxicity assays 
must take into account LPS contamination (99). The 
responsiveness to LPS appears to correlate with the 
stage of macrophage functional differentiation, there-
fore, if macrophages with lower levels of functional 
activity were exposed to contaminating doses of LPS they 
may become further activated, as noted previously (127). 
Further variations such as the stage of differentiation 
and consequent functional responsiveness are parameters 
not easily controlled, and are likely to be responsible 
for variability among different systems (65). 
A direct comparison of the data between the assays 
must take into account the differences in the two 
experimental systems. One employs direct examination of 
cytotoxicity while the other measures an index of 
cytotoxicity as judged by the release of radioisotope. 
The different methodologies involved with these assays 
may account for the different range of data obtained. 
Therefore, levels of activity between these assays 
cannot be compared directly. However, comparisons can 
70 
be made between groups within an experimental system and 
comparisons can be made between relative changes in both 
systems. The results of these experiments, have shown 
statistically that nearly parallel levels of extracel-
lular cytocidal activity for fungi and tumor cells 
exist. The only exception was in post-cytolytic 
activity where the tumoricidal capacity of the macro-
phages dropped to a level significantly lower than group 
I. This was not the case for fungicidal activity which 
returned to group I levels. The observed difference may 
relate to the total time required to accomplish the two 
assays; measurement of fungicidal activity was 73 h in 
duration, while measurement of tumoricidal activity 
required a total of 96 h. Likewise, the difference in 
culture time and the difference in actual assay time may 
contribute to the varied results, but has not been 
explored. Macrophages possess numerous physiological 
properties that may be modulated during the activation 
process. An expression of one such function, extracel-
lular cytocidal ability, may be related in some form to 
other macrophage functions. However, the parallel 
levels of cytocidal activity suggest that extracellular 
killing is the same for all macrophage groups employed 
in this investigation. 
The mechanism by which macrophages recognize and 
lyse various targets is poorly understood (2). However, 
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it is possible to speculate on a mechanism of killing by 
which the macrophages employed within this study lyse 
two diverse targets. The concept of the nonspecific 
response of macrophages originally proposed by Mackannas 
(77), does not explain or demonstrate how a macrophage 
recognizes, binds tq, and destroys targets recognized 
as foreign. The data obtained by many investigators 
off er a variety of theories regarding this matter 
(2,60,130). However, the data obtained in this study 
supports the.concept of similar interactive and func-
tional activities, regardless of the nature of the 
target. 
Complex cytocidal mechanisms for macrophage-
mediated destruction for a diverse set of target cells 
has been described (6). Each of a multitude of toxic 
substances has been proposed as the effector molecule 
for cytotoxic activity including; proteases, C3a, 
arginase, H2o2 , TNF, and cytotoxins. The primary 
reaction of macrophage activation could result in 
increased synthesis of factors mediating the cytotoxic 
activity (88). Alternatively, precursor formation, or 
accessory system development could assist in cytocidal 
activities (88). Macrophages could release these 
effector or precursor molecules, resulting in lysis 
various targets. 
The process of macrophage cytotoxicity is normally 
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considered to be cell-contact dependent. Therefore, 
upon recognition and binding of the target cell, a small 
surface area of intimate contact would be established 
(3). Such surface contact could trigger a series of 
metabolic events which allow the macrophage to secrete a 
vast array of cytotoxic compounds (5). These compounds 
would be localized between the macrophage and its 
target. The area of macrophage-target surface contact 
has been speculated to be protected from these compounds 
(3). Likewise, the effector molecules would be pro-
tected, both from dilution in the extracellular milieu, 
and from degradation by extracellular proteases or 
inhibitors (5). Under some conditions, the macrophage 
may not be protected from this concentrated assortment 
of toxic metabolites and several studies have shown 
deleterious effects of secretion products on macrophage 
membranes invoked during the course of target cell 
destruction (33). 
Binding of targets to receptors on the macrophage 
is thought to serve several functions in cytolysis 
(119). Two types of tumor cell binding exist; low level 
and high level. Low level-binding is a nonselective 
attachment between many cell pairs while high level-
binding allows only selective binding between tumor 
cells and activated macrophages (60). It is possible 
for macrophages to convert a weak nonselective binding 
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to stable binding if tight binding between macrophage 
and target cell occurs (113). 
Macrophages selectively bind tumor cells with 
specific cell markers to their surface. The biochemical 
determinants of the macrophage tumor cell receptor are 
unknown except for the participation of a trypsin-
sensi ti ve cell-binding site which is very similar to a 
receptor (113). However, unlike normal receptor-ligand 
interaction, energy is required to bind the tumor cell. 
Certain tumor cells have adapted their markers in such a 
way as to be resistant to recognition by certain cell 
types in certain strains of animals (2). 
Macrophages also possess receptors which recognize 
nonphosphorolated, terminal mannose, N-acetylglucosamine 
and fucose residues (24). Such a recognition mechanism 
provides a means for microbial binding prior to phago-
cytosis (11). The blockage of this calcium dependent 
receptor inhibits the binding of mannose by macrophages, 
indicating a specificity for mannose (119). This 
specificity is not enhanced or decreased by level of 
macrophage activation. Furthermore this mannose 
specific receptor diminishes in latter stages of 
activation (57). 
Different effector molecules may exist for dif-
ferent targets. The secretion of the multitude of 
cytocidal substances allows both for the specific 
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killing of targets by one mechanism and also for 
molecular synergism, resulting in enhanced cytocidal 
activity. For instance, specific mechanisms such as ROI 
have proven very effective against Candida while 
nonoxidative mechanisms seem only to mediate partial 
cytocidal effects (26). Conversely, secreted products 
such as TNF and cytotoxic factors have proven effective 
against tumor cells, while oxidative mechanism for 
tumoricidal activity are equivocal (91). Oxidative and 
non-oxidative means of cytocidal activity have been 
shown to cooperate in tumoricidal systems. H2o2 and 
cytotoxins combine for greater tumoricidal effect than 
either produces separately (60). 
The expression of nonspecific effector activities 
by macrophages differ with the nature of the target and 
its relationship to the macrophage. The activation for 
extracellular versus intracellular effector activity 
share many common characteristics but can ultimately be 
dissociated on the basis of the target, the responding 
cell, and inductive signal. The details of each 
effector function of activated macrophages are unique 
for each target and has been shown to be dependent upon 
the lymphokine which activates the macrophage (88). 
Therefore at one level, regulation may not be dictated 
by the target, but by the site, either intracellular or 
extracellular (88). For example, the alteration of 
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membranes associated with phagocytosis may regulate the 
cell and initiate intracellular killing mechanisms (96). 
It can be speculated that lymphokines which induce 
intracellular killing provide the same type of activa-
ting signal to the macrophage as that of phagocytosis. 
The regulation of extracellular killing is much 
more complex. Maximum antimicrobial activities against 
intracellular organisms is induced within 4 h regardless 
of the sequence in which the target, macrophage, and 
signal are presented. However, maximal extracellular 
killing requires the presence of macrophage, target and 
activation signal at the same time (88). Furthermore, 
any ingested cell could be killed by a combination of 
cytotoxic products concentrated within the phagosome. 
However, due to the nature of the killing process, the 
macrophage must recognize which extracellular cytocidal 
mechanism to induce for effective killing of a nonphago-
sotized organism. 
Evaluation of the extracellular killing mechanism 
employed in this study proves difficult for the fol-
lowing reason. The ability of the macrophage to kill 
two distinct targets, a single eukaryotic cell compared 
to a multiseptated hyphae implies utilization of 
different effector mechanisms. This is due to the 
variable susceptibility of fungal wall polymers of 
mannose as compared to the simple phospholipid bilayer 
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associated with tumor cells. 
These mechanisms may be regulated at two different 
levels. At the first level, the cell activates either 
intracellular or extracellular mechanisms of cytocidal 
activity. Destruction of two different extracellular 
targets may be induced by the same cytolytic mechanisms, 
which are activated by signals which trigger extracel-
lular killing mechanisms. Conversely, intracellular 
cytolytic activity would be activated by signals which 
would induce intracellular killing. 
The secondary level is more complex. It must be 
noted that several possibilities exist. First of all 
macrophages may recognize target cells by binding to 
them as a result of certain receptors (i.e. mannose) 
present on macrophages. This binding may then activate 
a particular cascade of products which could allow the 
macrophage to respond in an appropriate and specific 
manner to a stimulus. Secondly, all products of the 
cytotoxic potential may be released to the extracellular 
environment. The regulation of this release would be 
time dependent. Therefore, only at various time points 
in the maturation process would certain effector 
molecules be released. This may limit specific killing 
of targets yet would allow for nonspecific killing, 
albeit at various time points. 
Finally, functional subsets of macrophages which 
77 
were present upon maturation to macrophages would be 
activated against a specific target. These cells would 
be activated to mediate specific cytocidal effector 
mechanisms against specific predefined targets. 
Data from this study which shows parallel levels of 
cytocidal activity in four different groups of macro-
phages, against these two targets does not support the 
last possibility, that functional subsets exist. 
However, many investigators favor this explanation 
(22,96,127). 
Meltzer has proposed that all cytocidal mechanisms 
are enhanced first intracellular, then extracellular 
microbicidal activity, followed by tumoricidal activity 
(80). This study does not refute this concept, since 
the variance in time frames which may be required to 
observe this method of cytocidal activity utilized may 
not have been studied. However, in the context of this 
study, sequential effector function must be questioned 
since parallel increases and decreases in cytocidal 
activity were found with all groups of macrophages 
analyzed. Alternatively, extracellular killing for all 
targets may be parallel. 
It is entirely possible that macrophages, once 
activated for extracellular cytocidal activity recognize 
specific markers on target cells such as mannose or 
tumor cell membrane markers. Once bound the macrophage 
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would then rechannel cytocidal activity to specific 
mechanisms based on which receptors are bound. It has 
been shown that macrophages which are strongly tumori-
cidal and then challenged with schistosoma are only 
weakly cytolytic (88). While it is possible that 
sequential levels of functional activity may be invoked, 
experiments to assess specific recognition have not been 
performed. Other studies have shown that macrophages 
activated for a particular tumoricidal response do show 
levels of activity for other organisms, thus implying 
that activity against these targets appears in a 
secondary or nonspecific manner. 
Finally, this study has demonstrated that macro-
phages at various levels of activation possess varying 
levels of cytocidal activity. However, it is known that 
nonactivated macrophages possess higher levels of 
mannose specific receptors. Therefore, such macrophages 
would bind more readily to Candida. Once bound the 
Candida may activate the macrophage directly through 
binding, or indirectly through activation mechanisms 
similar to those described for LPS and lymphokines. 
The results obtained in this study emphasize many 
of the problems encountered when studying macrophage 
activation. Grouping, elicitation, cell targets and 
functional differences found in the different stages of 
activation all contribute to variability among results 
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(88). Any given population of cells may also vary due 
to state of the host and dose of antigenic stimuli. 
Therefore, during active infection or simulated condi-
tions of active infection, a maximum stimulus for 
macrophages occurs (130). Conditions of maximum 
stimulation, would be the most opportune time to 
comparitively study functional properties of macro-
phages. It has been suggested that these properties may 
occur and be lost at different rates within the popula-
tion (130). This renews the theory that separate 
subpopulations of effector cells display activated 
properties and could modulate the population as a whole 
(126). Despite the merits of this theory (130) the data 
collected herein would contradict it, since parallel 
functional levels of activity have been found in both 
the candidacidal and tumoricidal systems at each level. 
The only exception to this was macrophages incubated 
with LPS for 72 hrs. In this case the macrophages from 
both assays did return to a level near that of the 
resident macrophages. The tumoricidal assay dropped to 
a level even lower, probably due to reasons already 
discussed. Alternatively, the mechanism by which 
macrophages produce their cytocidal effects may be 
similar, which could explain in part the parallel 
cytocidal activity (88). 
A comparison of macrophage extracellular tumori-
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cidal activity, as judged by 51cr release assay, and 
fungicidal activity, as judged by inhibition of Candida 
albicans yeast formation following hyphal induction, has 
resulted in a strong correlation of activity with four 
separate macrophage treatment groups. This correlation 
indicates parallel levels of extracellular cytocidal 
activity over a range of the macrophage maturation 
groups and suggests similar mechanisms of extracellular 
killing. 
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SUMMARY 
This investigation compared the tumoricidal and candid-
acidal activity of four groups of murine macrophages. 
Resident macrophages (Group I) displayed the least 
cytocidal activity. Proteose peptone-elicited macro-
phages (Group II) showed a significant increase in 
cytocidal activity over group I (p<0.001) in both 
tumoricidal and fungicidal assays. Proteose peptone-
elicited, 18 h LPS-treated macrophages (Group III) 
displayed a significantly greater level of activity than 
either group I (p<0.001) or group II (p<0.001) macro-
phages in both tumoricidal and fungicidal assays. 
Proteose peptone-elicited, 72 h LPS-treated macrophages 
(Group IV) showed a decrease in fungicidal activity to a 
level near group I, while the tumoricidal activity 
dropped to a level significantly below group I (p<0.001) 
macrophages. These data indicate a parallel relation-
ship between the killing, via extracellular mechanisms, 
of both fungi and tumor cells by these four groups of 
macrophages. 
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